Live Breaking News & Updates on Wojciech Jurczak

Stay updated with breaking news from Wojciech jurczak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Wojciech Jurczak Discusses Changing Treatment Options for R/R DLBCL

Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discusses the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ....

Wojciech Jurczak , Diffuse Largeb Cell Lymphoma ,

Dr Wojciech Jurczak Gives Insight Into the Phase 2 L-MIND Trial in DLBCL

Wojciech Jurczak, MD, PhD, lead researcher on the L-MIND study evaluating a new treatment combination in diffuse large B-cell lymphoma (DLBCL), gave an overview of the trial results that were presented at the European Hematology Association 2023 Congress. ....

Wojciech Jurczak , Maria Sklodowska Curie National Research Institute Of Oncology , European Hematology Association ,

Pratia's study says: Poles, Bulgarians, and Ukrainians are ready to take part in clinical trials but too often trust the unverified information available online.

/PRNewswire/ Nearly half of Poles, Bulgarians, and Ukrainians are ready to participate in clinical trials, says the first-of-its-kind survey in CEE - by ARC. ....

Lukasz Beczkowski , Rynek Opinia , Wojciech Jurczak , Professor Wojciech Jurczak , Pratia Sa ,

Zandelisib Displays "Exemplary" Efficacy in Relapsed/Refractory Follicular Lymphoma

Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma. ....

Wojciech Jurczak ,

Zandelisib Displays "Exemplary" Efficacy in Relapsed/Refractory Follicular Lymphoma

Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma. ....

Wojciech Jurczak ,